Recombinant LH is equally effective as recombinant hCG in promoting oocyte maturation in a clinical in-vitro maturation programme: a randomized study.

What Was Tested

The paper reports a study of Chorionic Gonadotropin, published as a randomized controlled trial.

Fertilization treatment using oocytes matured in vitro from pre-ovulatory follicles has many potential applications.

It minimizes the risk of severe ovarian hyperstimulation and is an alternative for women with polycystic ovary syndrome who may have problems regarding stimulation for IVF.

Who Took Part

The study group was 73 women.

The age groups tagged for this paper are adults, women only.

From a randomized study of 73 women in an IVF programme, 36 subjects with 228 oocytes were allocated for oocyte maturation in culture medium with recombinant hCG, and 37 subjects with 256 oocytes for maturation with recombinant LH.

During the same period, 32 women outside the study underwent 38 individually tailored IVM treatments.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Chorionic Gonadotropin and who got the comparison, which limits bias.

The primary outcome was the rate of nuclear maturation of oocytes to metaphase II.

What Was Measured

PubMed files the paper under topics including Cell Nucleus, Cellular Senescence, Chorionic Gonadotropin, Cleavage Stage, Ovum, Culture Techniques, Embryo Transfer and Fertilization.

What This Means in Plain Language

The paper is a randomized study of Chorionic Gonadotropin in 73 women.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Human reproduction (Oxford, England)), a journal based in England.

More context: the related hCG (human chorionic gonadotropin) library page, all human trials.